VIVUS, Inc. (NASDAQ: VVUS) is headed for the top early on in the trading session this morning and for good reason. The company announced positive preliminary results from a clinical trial. Of course, positive results tend to lead to excitement among investors who are pushing the stock for the sky this morning. Today, we’ll talk about:
- The clinical results;
- what we’re seeing from VVUS as a result; and
- what we’ll be watching for ahead.
VVUS Announces Positive Clinical Results
As mentioned above, VIVUS is having an incredible day in the market today after providing a clinical update. In a press release issued early this morning, the company announced positive preliminary results from a Phase 1 clinical study. During the study, the company worked to evaluate the pharmacokinetic profile of VI-0106 in healthy volunteers. Currently, VVUS is developing VI-0106 as a treatment for pulmonary arterial hypertension (PAH), which is a degenerative disease that makes it difficult for the heart to pump blood through the lungs to be oxiginated. As a result, the disease is known to lead to heart failure.
While there are PAH treatments currently on the market, these treatments only address symptoms and slow progression. However, they do not prevent progression. As a result, there is a strong medical need for a treatment that can prevent the progression of this devastating ailment. In a statement, John Amos, CEO at VVUS, had the following to offer:
The positive Phase 1 data from this study of VI-0106 in healthy volunteers support continued evaluation of this investigational candidate in PAH patients… The worldwide and U.S. markets for PAH therapies were approximately $4.5 billion and $2.7 billion, respectively, in 2015, and we believe that VI-0106 has the potential to capture significant market share as a first-in-class therapy with a novel mechanism of action. We are exploring a variety of strategies for leveraging this collection of data to advance this program consistent with our goals of working toward profitability and reducing our corporate debt.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. In the case of VIVUS, the news proved to be overwhelmingly positive. After all, if this treatment does prove to be an option to prevent the progression of PAD, the asset would prove to be highly valuable. So, it’s no surprise that with the strong preclinical results, investors are sending the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:13), VVUS is trading at $0.83 per share afgter a gain of $0.083 per share or 11.12% thus far today.
Stop wasting your time! Start finding winning trades in minutes with trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on VVUS. In particular, we’re interested in following the story surrounding the company’s continued work to bring VI-0106 to market as early data seems to be incredibly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!